logo

For the Inventor, By the Inventor

Charles Joel Arntzen

Ithaca, NY, United States of America

Charles Joel Arntzen

LinkedIn

This inventor holds 27 USPTO granted patents and 3 EPO patents, primarily in Plant-Based Vaccines. Top assignees: Arizona State University, Research Development Foundation, Boyce Thompson Institute for Plant Research. Active years: 1998-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles Joel Arntzen. Retrieved from https://idiyas.com/inventor/charles-joel-arntzen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27

% Patents Active = 63.0


Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 273(Granted Patents)


Location History:

  • Tompkins, NY (US) (1998)
  • Tempe, AZ (US) (2004)
  • Gold Canyon, NY (US) (2009)
  • Superstition Mountain, AZ (US) (2008 - 2011)
  • Ithaca, NY (US) (2001 - 2012)
  • Gold Canyon, AZ (US) (2013 - 2018)

Company Filing History:

goldMedal9 out of 2,164 
 
Arizona State University
 patents
silverMedal6 out of 299 
 
Research Development Foundation
 patents
bronzeMedal5 out of 69 
 
Boyce Thompson Institute for Plant Research
 patents
4. 2 out of 314 
 
Health Research, Inc.
 patents
5. 2 out of 1,328 
 
Texas A&M University System
 patents
6. 5 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2018

Loading Chart...
Loading Chart...
Areas of Expertise:
Geminiviral Vector
Mucosal Immunization
Glycoprotein Fusions
Transgenic Plants
Vaccine Production
Monoclonal Antibody
Norovirus Detection
Triterpene Compositions
Genetic Changes
Allergen Gene Silencing
Recombinant Proteins
Oral Immunology
27 patents (USPTO):Explore Patents
1. 10125373 - Geminiviral vector for expression of rituximab (2018-11-13),
2. 10080799 - Methods and compositions related to glycoprotein-immunoglobulin fusions (2018-09-25),
3. 9766239 - Synbodies for detection of human norovirus (2017-09-19),
4. 9585954 - Mucosal immunization (2017-03-07),
5. 9506079 - DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants (2016-11-29),
6. 9439958 - Stabilized virus like particles having enhanced mucosal immunogenicity (2016-09-13),
7. 8513397 - DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants (2013-08-20),
8. 8324177 - Triterpene compositions and methods for use thereof (2012-12-04),
9. 8217228 - Down-regulation and silencing of allergen genes in transgenic peanut seeds (2012-07-10),
10. 7985435 - Triterpene compositions and methods for use thereof (2011-07-26),
11. 7927833 - Composition and method for enhancing immune response (2011-04-19),
12. 7879338 - Vectors and methods for immunization against norovirus using transgenic plants (2011-02-01),
13. 7670632 - Triterpene compositions and methods for use thereof (2010-03-02),
14. 7572466 - Oral immunology using plant product containing a non-enteric pathogen antigen (2009-08-11),
15. 7527810 - Oral immunology using plant product containing hepatitis surface antigen (2009-05-05),

As an assistant focused on innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide information about inventor Charles Joel Arntzen based on the data provided.

Title: Exploring the Innovations of Charles Joel Arntzen

Introduction: Charles Joel Arntzen is a prolific inventor based in Ithaca, NY, with an impressive track record of 26 patents to his name. His groundbreaking work has notably advanced plant transient expression technology and immune response elicitation methods.

Latest Patents:

1. Geminiviral Vector for Expression of Rituximab: Arntzen's innovative patent describes a novel system utilizing a single vector or multiple separate vectors for optimizing the expression of Rituximab in plant cells. This advancement eliminates the need for non-competing viruses, enhancing the commercial viability of producing Rituximab.

2. Methods and Compositions Related to Glycoprotein-Immunoglobulin Fusions: Arntzen's patent focuses on compositions and methods for eliciting immune responses against HCV antigens, specifically targeting HCV glycoproteins E1 and E2. This work represents a significant contribution to the field of immunology.

Career Highlights: Arntzen has contributed his expertise to esteemed organizations such as the Research Development Foundation and the Boyce Thompson Institute for Plant Research. His dedication to innovation has led to transformative developments in plant biotechnology and immunology.

Collaborations: Throughout his career, Arntzen has collaborated with notable professionals in the field, including Hugh S Mason and Jordan U Gutterman. These collaborations have enriched his work and propelled advancements in plant-based pharmaceutical production and immune system research.

Conclusion: Charles Joel Arntzen's pioneering work in plant expression technology and immunology has left an indelible mark on the scientific community. His patents stand as a testament to his innovative spirit and commitment to pushing the boundaries of what is possible in biotechnology and healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…